

Zydus launches 'Tenglyn', the most affordable gliptin for diabetics in India

Ahmedabad, India, 20 November 2015

Zydus Cadila launches Tenglyn – Teneligliptin 20 mg tablets, which belongs to a new class of oral anti-diabetic agents, Gliptins. With an aim to make this important therapy affordable and accessible to diabetic patients, Tenglyn is being priced at just Rs. 7 per tablet which is almost 1/6th the price at which the Gliptins were initially launched in India.

Gliptins have shown promise in achieving glycemic control without deteriorating beta cell function and is one of the most recent advancements in diabetes care and management. Research in the field of anti-diabetic therapy seeks to address the problems of hypoglycemia, GI side effects, lactic acidosis, weight gain, CV risks etc., which pose a major challenge in the treatment of diabetes.

Speaking on the development, Dr. Sharvil Patel, Deputy Managing Director, Zydus Cadila, said, "At Zydus, our endeavour has been to bring new therapies and innovations that address the two primary challenges in India of accessibility and affordability. Diabetes, as we know, is becoming a major health burden globally. We remain committed to this fight against diabetes and with Tenglyn we provide patients suffering from diabetes access to this advanced treatment at the most affordable cost."

The incidence of diabetes is an alarming one with the number of diabetics in the world is estimated to be over 360 million. With a patient population of almost 65 million diabetics in India, access to affordable therapy is critical. The launch of Tenglyn comes as a boon and will help a large number of patients in India suffering from Type II diabetes, access the most affordable gliptin therapy and benefit from it.

The group's 'win over diabetes' programme has been helping patients access newer ground breaking therapies. The group had earlier launched Lipaglyn™ (Saroglitazar), India's first NCE which is a breakthrough therapy in the treatment of diabetic dyslipidemia and hypertriglyceridemia. It has over 20 discovery programmes in the areas of diabetes and other cardio-metabolic disorders.

About Zydus

Headquartered in Ahmedabad, India, Zydus Cadila is an innovative, global pharmaceutical company that discovers, manufactures and markets a broad range of healthcare therapies. The group employs over 16,500 people worldwide including over 1200 scientists engaged in R & D and is dedicated to creating healthier communities globally. As a leading healthcare provider, it aims to become a global research-based pharmaceutical company by 2020. The group has a strong research pipeline of NCEs, biologics and vaccines which are in various stages of clinical trials including late stage.